Inactive Instrument

News Teva Pharmaceutical Industries Limited TEL AVIV STOCK EXCHANGE

Equities

IL0006290147

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Teva to Host Conference Call to Discuss Second Quarter 2024 Financial Results at 8 a.m. ET on July 31, 2024	Jul. 02	BU
Sector Update: Health Care Stocks Retreat Late Afternoon	Jul. 01	MT
Sector Update: Health Care Stocks Slipping in Afternoon Trading	Jul. 01	MT
Teva Pharmaceuticals Faces FTC Probe on Patent Listings	Jul. 01	MT
Correction: Top Midday Stories: Boeing to Acquire Spirit AeroSystems; Robinhood Acquires Pluto; FTC Probes Teva; BlackRock Acquires Preqin; SCOTUS Grants Trump Some Immunity	Jul. 01	MT
Teva Pharmaceutical Faces FTC Investigation for Patents, Washington Post Says	Jul. 01	DJ
Top Midday Stories: Boeing to Acquire Spirit AeroSystems; Robinhood Acquires Pluto; FTC Probes Teva; BlackRock Acquires Preqin; SCOTUS Grants Trump Some Immunity	Jul. 01	MT
Teva Pharmaceuticals Faces FTC Probe on Patent Listings	Jul. 01	MT
Teva Pharmaceuticals Faces FTC Probe on Patent Listings	Jul. 01	MT
FTC Opens Investigation Into Teva Pharmaceuticals	Jul. 01	MT
FTC Opens Investigation Into Teva Pharmaceuticals, Washington Post Reports	Jul. 01	MT
Vanda Pharmaceuticals Says Federal Court Allows Patent Lawsuit Over Hetlioz	Jul. 01	MT
New AJOVY® (fremanezumab) Migraine Prevention Data Challenges Treatment Pauses	Jun. 28	BU
Teva Pharmaceutical Industries Ltd Announces New AJOVY® (Fremanezumab) Migraine Prevention Data Challenges Treatment Pauses	Jun. 28	CI
Jefferies Adjusts Price Target on Teva Pharmaceutical Industries to $23 From $19, Maintains Buy Rating	Jun. 27	MT
Global markets live: UBS, Boeing, AT&T, Rivian, Nvidia, Tesla...	Jun. 25
Teva Pharmaceutical Pays $750 Million to Resolve Tax-Related Litigation	Jun. 25	MT
Teva settles tax dispute in Israel with $750 mln payment	Jun. 25	RE
Teva Announces Launch of Authorized Generic of Victoza, in the United States	Jun. 25	AQ
Teva Reaches Agreement With the Israel Tax Authority to Resolve All Pending Litigation for the Company's Taxable Years 2008-2020	Jun. 25	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Teva Pharmaceutical Industries isn't out of the woods yet

February 01, 2024 at 04:41 am EST

INTERVIEW - Richard Francis, CEO of Teva Pharmaceutical: solid quarter, full-year forecasts raised

August 02, 2023 at 03:19 pm EDT